HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
STXS
Stereotaxis, Inc.
STXS lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
STXS Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Under pressure | |
| Weak | |
| Unavailable |
STXS's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
STXS PE Valuation
STXS has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
STXS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
STXS has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has the edge over STXS on earnings, with more consistent year-over-year improvement.
STXS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.24 | +$0.05 |
| Q1 2026 | -$0.24 | +$0.07 |
| Q4 2025 | -$0.25 | +$0.05 |
| Q3 2025 | -$0.28 | -$0.01 |
| Q2 2025 | -$0.29 | -$0.03 |
| Q1 2025 | -$0.31 | -$0.05 |
| Q4 2024 | -$0.30 | -$0.03 |
| Q3 2024 | -$0.27 | $0.00 |
STXS is still losing money, but less than at its worst: $0.24 per share over the past year, against $0.31 at its worst in early 2025.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over STXS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over STXS on profitability, with a higher operating margin.
STXS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $7.7M | -13% |
| Q1 2026 | $6.3M | -16% |
| Q4 2025 | $8.6M | +36% |
| Q3 2025 | $7.5M | -19% |
| Q2 2025 | $8.8M | +95% |
| Q1 2025 | $7.5M | +8.6% |
| Q4 2024 | $6.3M | +39% |
| Q3 2024 | $9.2M | +18% |
STXS's revenue has slid since its 2024 peak: $8M last quarter, down 13% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -60% | -14 points |
| Q1 2026 | -95% | -16 points |
| Q4 2025 | -65% | +55 points |
| Q3 2025 | -88% | -19 points |
| Q2 2025 | -45% | +89 points |
| Q1 2025 | -79% | -10 points |
| Q4 2024 | -120% | -4.1 points |
| Q3 2024 | -69% | +3.3 points |
STXS's operating margin was −60% last quarter, down 14 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the stronger cash trend. Its trailing FCF is down 84% versus its history, compared with STXS at down 101%.
STXS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$3.5M | -$1.7M |
| Q4 2025 | -$4M | -420% |
| Q3 2025 | -$4.2M | +$135K |
| Q4 2024 | $1.3M | +$3.7M |
| Q3 2024 | -$4.3M | -$3.4M |
| Q4 2023 | -$2.4M | +$482K |
| Q3 2023 | -$977K | +$1.8M |
| Q2 2023 | -$2.9M | -$1.2M |
STXS has burned cash in almost every quarter: −$16M over the past year, against −$7M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over STXS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
STXS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.2% | +1.1M shares |
| 1 year | +14% | +12.1M shares |
| 3 years | +23% | +19M shares |
| 5 years | +32% | +24.5M shares |
| Available history | +56% | +35.7M shares |
STXS has 100M diluted shares, up 14% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
STXS Net Leverage
STXS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
STXS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 31.1 | Neutral |
| Stochastic | 18.5 | Oversold |
STXS's weekly RSI is 31 (neutral) and its Stochastic is 18 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
STXS PE vs Healthcare Sector
STXS has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
STXS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.05 | 19% below |
| 20 week MA | $1.28 | 34% below |
| 50 week MA | $1.76 | 52% below |
| 100 week MA | $2.05 | 59% below |
| 200 week MA | $2.02 | 58% below |
STXS is in a downtrend: it's below all five of its weekly moving averages, and 58% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over STXS on returns for 2026, with the stronger performance.
STXS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.03 | $5.14 | +2.2% |
| 2021 | $5.14 | $6.26 | +22% |
| 2022 | $6.26 | $2.03 | -68% |
| 2023 | $2.03 | $1.75 | -14% |
| 2024 | $1.75 | $2.29 | +31% |
| 2025 | $2.29 | $2.46 | +7.4% |
| 2026 YTD | $2.46 | $0.85 | -65% |
STXS is down 65% so far in 2026, after finishing higher in four of the previous six years.